Funder: Breakthrough T1D
Due Dates: January 28, 2026 (Letter of Intent) | March 11, 2026 (Full proposal)
Funding Amounts: Up to $900,000 total for up to 3 years (including 10% indirect costs); budgets exceeding this require pre-approval.
Summary: Supports translational research to improve vascularization and monitoring of islet replacement therapies for type 1 diabetes, with a focus on clinical applicability.
Key Information: LOI approval required before full proposal; both academic and industry applicants eligible.